Dayla HealthVisit Website →
← Back to blog

Verify Compounded Semaglutide: FDA Warnings and a 5‑Step Checklist

October 5, 2026
Verify Compounded Semaglutide: FDA Warnings and a 5‑Step Checklist

Most compounded semaglutide vials contain either semaglutide base or a salt form such as semaglutide sodium or semaglutide acetate, often combined with additives like vitamin B12, B6, niacinamide, glycine, or levocarnitine. These products are not FDA-approved, and many lack the standard testing that verifies potency, purity, and ingredient accuracy.

TL;DR:

  • Most compounded semaglutide products are not FDA-approved and often contain salt forms of semaglutide, which may alter absorption and effectiveness.
  • Common additives like vitamin B12, B6, and niacinamide are included without clinical evidence of safety or benefit, often in nearly half of compounded formulations.
  • Regulatory authorities warn that substitution of salt forms or untested ingredients increases safety risks and reduces product reliability, especially as supply stabilizes.
  • Laboratory tests reveal impurities, potency inconsistencies, and contamination risks due to lack of standardized manufacturing and storage conditions.
  • Patients should verify compounded products with lot-specific certificates of analysis, source documentation, and preferably under clinician supervision to ensure safety.
Daylahealth
Explore GLP-1 Weight Loss Options
Daylahealth offers GLP-1 weight loss prescriptions and peptides for health-conscious people seeking weight loss support.
Visit Daylahealth

Table of Contents

What the active ingredient can be: semaglutide base versus salt forms

FDA-approved semaglutide products use semaglutide base, a specific molecular form chosen for predictable absorption and stability. Compounding pharmacies sometimes substitute salt forms, including semaglutide sodium or semaglutide acetate, because they can be easier to produce or more soluble during manufacturing.

The FDA warns that these salt forms are different active ingredients from the semaglutide base used in approved drugs, and their pharmacologic equivalence to approved products is unknown. A change in salt form can shift how the drug is absorbed, how the body processes it, and how the immune system responds to it.

A few distinctions matter for anyone reviewing a compounded product's label:

  • Semaglutide base is the form used in FDA-approved drugs and carries established pharmacokinetic data.
  • Semaglutide sodium and semaglutide acetate are salt forms sometimes substituted by compounders for manufacturing convenience.
  • Switching salt forms can alter potency, stability, and how predictably the drug behaves once injected.

Patients reviewing a compounded prescription should ask which form the pharmacy used and why, since the answer affects both safety and expected results. Our breakdown of semaglutide base versus salt forms covers the verification steps in more detail.

Typical additives and excipients found in compounded formulations

Compounding pharmacies frequently add other ingredients to semaglutide vials, marketed as ways to reduce side effects or boost results. A 2026 Stanford review found that many compounded GLP-1 products include additional substances beyond the active peptide.

The most commonly reported additives include:

  • Cyanocobalamin, the synthetic form of vitamin B12, often added for energy claims.
  • Pyridoxine, or vitamin B6, sometimes included to address nausea.
  • Niacinamide, a form of vitamin B3, marketed for metabolic support.
  • Glycine, an amino acid added as a stabilizer or filler.
  • Levocarnitine, promoted for fat metabolism despite limited supporting data.

Nearly 50% of surveyed compounded GLP-1 products combined semaglutide with substances like cyanocobalamin, glycine, niacinamide, docusate, or ondansetron, according to the 2026 Stanford review. That prevalence means a majority of patients buying compounded products may receive a blend rather than a single active ingredient, often without being told why.

Compounders typically justify these additions as nausea mitigation or general wellness support, but no clinical trials have tested these specific combinations for safety or effectiveness. The rationale is largely a marketing differentiator, not a documented therapeutic benefit.

Regulatory guidance and FDA safety concerns about compounded GLP-1 products

The FDA has issued direct warnings about the compounded GLP-1 market, specifically flagging salt-form substitutions and fraudulent products circulating without proper oversight. The agency's position is that compounded products using semaglutide sodium or acetate introduce uncertainty because their equivalence to approved drugs has not been established.

Compounding exemptions historically existed to fill gaps during drug shortages, and that context shaped much of the current market. The FDA has since clarified that products considered "essentially copies" of commercially available drugs may lose their compounding exemption once national supply stabilizes.

Key regulatory points worth understanding:

  • Compounding exemptions apply primarily during documented drug shortages, not indefinitely.
  • A product nearly identical to an approved drug can lose its legal compounding pathway as supply recovers.
  • The FDA has flagged fraudulent compounded products entering the market under misleading labeling.

As national GLP-1 supply stabilizes, the legal footing for many compounded semaglutide products continues to narrow.

Safety risks: impurities, chemical reactions, stability, and dosing errors

Laboratory testing has uncovered safety concerns that go beyond ingredient labeling. Analytical findings on compounded tirzepatide-B12 products identified a widespread impurity caused by a chemical reaction between the peptide and B12 analogs, a reaction product that would not appear in a single-ingredient, FDA-approved formulation.

Illustration of peptide impurity formation

A narrative review for health care providers warns that compounded semaglutide products often lack the consistent quality controls required of approved drugs, contributing to documented dosing errors and adverse events.

Common risk factors include:

  • Variable potency between batches due to inconsistent manufacturing standards.
  • Storage and shipping conditions that can degrade peptide stability before the vial reaches you.
  • Dosing errors linked to unclear concentration labeling or unfamiliar administration routes.
  • Fraudulent batches entering the supply chain under legitimate-sounding pharmacy names.

Pro Tip: Store compounded peptides exactly as instructed and discard any vial with visible discoloration, particles, or inconsistent clarity, since these changes can signal degradation or contamination.

The clinical consequences of impurities found in B12-combined formulations remain unknown, which is itself a reason for caution rather than reassurance. Our guide to injection sites and safe administration covers practical steps for minimizing dosing mistakes at home.

How to verify what's actually in your compounded semaglutide

Verification is the single most useful habit a patient can build before starting a compounded product. A peer-reviewed review for providers notes that certificates of analysis, including HPLC or mass spectrometry impurity profiles and potency assays, are the most practical way to confirm a vial's actual contents.

Before accepting a compounded prescription, take these steps:

  1. Request a lot-specific certificate of analysis showing potency, purity, and sterility testing results.
  2. Ask for documentation on the active pharmaceutical ingredient source, including whether it is semaglutide base or a salt form.
  3. Confirm whether the compounding facility is registered as 503A or 503B, since oversight requirements differ between the two.
  4. Request a full ingredient list with exact concentrations rather than a general description.
  5. Watch for red flags: vague "proprietary blend" language, unproven administration routes marketed without evidence, or any refusal to provide a certificate of analysis.

Our five-check safety guide walks through each of these verification steps in more detail.

Publisher perspective and how we approach semaglutide safety

We built our GLP-1 program around clinician oversight rather than unsupervised purchasing. Every patient completes an online intake reviewed by a clinician before any prescription is approved, and our product pages describe the formulation details patients are entitled to ask about.

Supervised prescribing matters because a clinician can flag interactions, confirm dosing, and catch warning signs that a patient reviewing a label alone might miss. Verified sourcing and lot-specific testing reduce the chances of the impurities and potency inconsistencies documented in compounded product analyses.

If you are evaluating a semaglutide option, ask for a certificate of analysis, consult a clinician before starting, and consider practical guidance from this semaglutide weight loss plateau tips checklist to manage expectations and next steps during treatment.

When compounded semaglutide might be reasonable and when to avoid it

Compounding served a real purpose during documented shortages of approved semaglutide, giving patients an option when pharmacies could not fill prescriptions. That justification weakens as national supply stabilizes and FDA guidance narrows which compounded products remain lawful.

Our practical rule: favor verified, lot-tested, clinician-supervised options whenever they are available, and treat unverifiable compounded vials as a risk rather than a bargain. The ingredients in your vial should never be a guess.

— Flexible

How we help patients get verified semaglutide safely

We offer clinician-reviewed GLP-1 plans with clinical evaluation and ongoing care coaching.

Daylahealth

Current prices for our GLP-1 plans are available on the pricing page of our website.

Visit our GLP-1 treatment page to start an intake and get a clinician review before your first shipment.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

FAQ

What do they put in compounded semaglutide?

Compounded semaglutide may contain either semaglutide base or a salt form such as semaglutide sodium or acetate, along with additives like cyanocobalamin, pyridoxine, niacinamide, glycine, or levocarnitine. A 2026 Stanford review found these additions common but not clinically studied as combinations.

What are the ingredients in semaglutide?

FDA-approved semaglutide, as listed on the Ozempic prescribing label, contains semaglutide base along with disodium phosphate dihydrate, propylene glycol, phenol, and water for injection at a pH near 7.4. Compounded versions may differ in both active ingredient form and excipients, and rarely publish this level of detail.

Is semaglutide compounded with B12 safe?

Combining semaglutide with B12 analogs has been linked to a documented chemical reaction that produces new impurities, according to analytical testing on compounded peptide-B12 products. The clinical significance of these impurities is not yet known, which makes the combination a genuine safety uncertainty rather than a proven risk.

What is the safest compounded semaglutide?

The safest approach is a compounded product backed by a lot-specific certificate of analysis, clear documentation of the active ingredient source, and oversight from a licensed clinician. A narrative review for providers emphasizes that consistent quality controls, not marketing claims, separate safer products from risky ones.

Sources

For readers who want to verify these claims directly, the sources below cover FDA guidance, peer-reviewed analyses, and labeling data referenced throughout this article.